Integrating Business Impact Analysis, Scenario-Based FMEA, and Business Continuity Planning in Pharmaceutical Manufacturing: A Product-Level Case Study
Authors:
- Ivana MitrevskaIMIvana Mitrevska
- Sandra BoshnachkiSBSandra Boshnachki
- Sonja BurcevskaSBSonja Burcevska
- Elizabeta KaradzinskaEKElizabeta Karadzinska
- Olivera PanevaOPOlivera Paneva
Open Access
- 22 August 2026
- journal article
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 22 (1)
Abstract
No abstract availableAll Related Versions
This publication has 22 references indexed in Scilit:
- Causes and management of drug shortages: A scoping reviewResearch in Social and Administrative Pharmacy, 2025
- Impact of Supply Chain Disruptions and Drug Shortages on Drug Utilization: A Scoping ReviewPharmacoepidemiology and Drug Safety, 2025
- Reasons for supply side driven drug shortages – A mixed-methods study on first-level, higher-level, and root causes from the perspective of marketing authorization holdersResearch in Social and Administrative Pharmacy, 2023
- Pharmaceutical supply chain reliability and effects on drug shortagesComputers & Industrial Engineering, 2022
- Organizational resilience: a capability-based conceptualizationBusiness Research, 2019
- Building up Resilience in a Pharmaceutical Supply Chain through Inventory, Dual Sourcing and Agility CapacityOmega, 2017
- A state-of-the-art review of FMEA/FMECA including patentsComputer Science Review, 2017
- Association Between US Norepinephrine Shortage and Mortality Among Patients With Septic ShockJAMA, 2017
- Integrated business continuity and disaster recovery planning: Towards organizational resilienceEuropean Journal of Operational Research, 2015
- Risk evaluation approaches in failure mode and effects analysis: A literature reviewExpert Systems with Applications, 2013